Biomea Fusion (BMEA)
(Real Time Quote from BATS)
$5.96 USD
+0.19 (3.29%)
Updated Aug 8, 2024 01:16 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Biomea Fusion, Inc. (BMEA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$23.86 | $60.00 | $5.00 | 313.52% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Biomea Fusion, Inc. comes to $23.86. The forecasts range from a low of $5.00 to a high of $60.00. The average price target represents an increase of 313.52% from the last closing price of $5.77.
Analyst Price Targets (7 )
Broker Rating
Biomea Fusion, Inc. currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, five are Strong Buy, representing 62.5% of all recommendations. A month ago, Strong Buy represented 62.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.75 | 1.75 | 1.75 | 1.75 | 1.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/10/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Hold |
6/7/2024 | Scotiabank | George Farmer | Strong Buy | Strong Buy |
6/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/7/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/7/2024 | H.C. Wainwright & Co. | Joseph Pantginis | Strong Buy | Strong Buy |
5/3/2024 | Piper Sandler | Joseph M Catanzaro | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 8 |
Average Target Price | $23.86 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | -1.04 |